PCM
IONS icon

Peregrine Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Peregrine Capital Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-131,630
Closed -$5.27M – 343
2024
Q3 		$5.27M Sell
131,630
-394
-0.3% -$18.3K 0.16% 209
2024
Q2 		$6.29M Buy
132,024
+13,426
+11% +$551K 0.18% 196
2024
Q1 		$5.14M Buy
118,598
+10,774
+10% +$514K 0.15% 236
2023
Q4 		$5.45M Sell
107,824
-18,569
-15% -$889K 0.16% 218
2023
Q3 		$5.73M Sell
126,393
-22,805
-15% -$941K 0.17% 223
2023
Q2 		$6.12M Sell
149,198
-49
-0% -$1.88K 0.17% 230
2023
Q1 		$5.33M Buy
149,247
+17,536
+13% +$658K 0.15% 237
2022
Q4 		$4.97M Buy
131,711
+8,315
+7% +$350K 0.16% 234
2022
Q3 		$5.46M Sell
123,396
-6,828
-5% -$288K 0.18% 224
2022
Q2 		$4.82M Sell
130,224
-96
-0.1% -$3.62K 0.15% 241
2022
Q1 		$4.83M Sell
130,320
-9,401
-7% -$308K 0.11% 246
2021
Q4 		$4.25M Buy
139,721
+3,934
+3% +$124K 0.09% 251
2021
Q3 		$4.55M Sell
135,787
-26,741
-16% -$1.01M 0.09% 250
2021
Q2 		$6.48M Sell
162,528
-9,820
-6% -$385K 0.12% 254
2021
Q1 		$7.75M Sell
172,348
-5,956
-3% -$332K 0.14% 247
2020
Q4 		$10.1M Buy
178,304
+1,020
+0.6% +$50.8K 0.19% 230
2020
Q3 		$8.41M Sell
177,284
-16,746
-9% -$930K 0.22% 152
2020
Q2 		$11.4M Sell
194,030
-28,312
-13% -$1.57M 0.33% 118
2020
Q1 		$10.5M Buy
222,342
+11,499
+5% +$641K 0.38% 110
2019
Q4 		$12.7M Buy
210,843
+16,514
+8% +$984K 0.32% 127
2019
Q3 		$11.6M Buy
194,329
+6,768
+4% +$441K 0.32% 128
2019
Q2 		$12.1M Sell
187,561
-1,527
-0.8% -$108K 0.3% 139
2019
Q1 		$15.3M Sell
189,088
-78,404
-29% -$5.06M 0.38% 119
2018
Q4 		$14.5M Sell
267,492
-1,890
-0.7% -$96.4K 0.41% 108
2018
Q3 		$13.9M Sell
269,382
-57,383
-18% -$2.7M 0.33% 133
2018
Q2 		$13.6M Buy
+326,765
New +$14.5M 0.34% 128

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TBC
Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return

Peregrine Capital Management's IONS Position: Q4 2024 in Review

Peregrine Capital Management sold out of Ionis Pharmaceuticals (IONS) in Q4 2024, closing a stake of 131,630 shares — an estimated $5.27M sold.

Peregrine Capital Management first reported a position in IONS in Q2 2018 and held it in 26 quarters. The position peaked at $15.3M in Q1 2019. 355 funds tracked by Wall St. Rank hold IONS as of Q4 2024.

  • Peregrine Capital Management reported no remaining Ionis Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Peregrine Capital Management sold 131,630 Ionis Pharmaceuticals shares in Q4 2024, an estimated $5.27M.
  • Peregrine Capital Management first reported a position in Ionis Pharmaceuticals in Q2 2018 and held it in 26 quarters.
  • Peregrine Capital Management's Ionis Pharmaceuticals position peaked at $15.3M in Q1 2019.
  • 355 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2024.

Based on Peregrine Capital Management's 13F filing for Q4 2024, filed 31 Jan 2025.